Werner Anne, Röhm Klaus-Heinrich, Müller Hans-Joachim
Department of Medicine, Institute of Physiological Chemistry, Philipps-University Marburg, D-35043 Marburg, Germany.
Biol Chem. 2005 Jun;386(6):535-40. doi: 10.1515/BC.2005.063.
The enzyme L-asparaginase is a crucial component in the treatment of acute lymphoblastic leukemia (ALL). As all asparaginases in clinical use are derived from microorganisms, immunological reactions are the most important adverse events associated with asparaginase treatment. Two different methods, phage display and the SPOTs method, were used for the determination of clinically relevant epitopes. Comparison of the results showed that essentially the same domains were identified by the two methods, and thus ascertainment of relevant epitopes can be assumed. Determination of the specificity of the epitopes will be performed with serum from patients with different modes of immunological reactions and from individuals without evidence of an immune response after asparaginase administration.
L-天冬酰胺酶是治疗急性淋巴细胞白血病(ALL)的关键成分。由于临床使用的所有天冬酰胺酶均来源于微生物,免疫反应是与天冬酰胺酶治疗相关的最重要不良事件。两种不同的方法,即噬菌体展示法和SPOTs法,被用于确定临床相关表位。结果比较表明,两种方法鉴定出的结构域基本相同,因此可以假定相关表位已确定。将使用来自具有不同免疫反应模式的患者以及在给予天冬酰胺酶后无免疫反应证据的个体的血清来确定表位的特异性。